Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,101,788
  • Shares Outstanding, K 53,772
  • Annual Sales, $ 91,370 K
  • Annual Income, $ -147,030 K
  • 60-Month Beta 0.24
  • Price/Sales 12.38
  • Price/Cash Flow N/A
  • Price/Book 2.26
Trade PRTA with:

Options Overview Details

View History
  • Implied Volatility 68.30% ( -1.10%)
  • Historical Volatility 56.69%
  • IV Percentile 40%
  • IV Rank 10.51%
  • IV High 312.37% on 12/15/23
  • IV Low 39.63% on 09/05/23
  • Put/Call Vol Ratio 2.50
  • Today's Volume 28
  • Volume Avg (30-Day) 80
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 4,031
  • Open Int (30-Day) 4,123

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -1.22
  • Number of Estimates 7
  • High Estimate -1.09
  • Low Estimate -1.38
  • Prior Year -1.03
  • Growth Rate Est. (year over year) -18.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.52 +10.04%
on 05/29/24
23.62 -9.06%
on 05/17/24
+0.14 (+0.66%)
since 05/10/24
3-Month
19.52 +10.04%
on 05/29/24
29.00 -25.93%
on 03/13/24
-6.06 (-22.00%)
since 03/12/24
52-Week
19.52 +10.04%
on 05/29/24
77.13 -72.15%
on 06/13/23
-51.53 (-70.58%)
since 06/12/23

Most Recent Stories

More News
Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

RHHBY : 34.0900 (+1.73%)
BMY : 42.41 (-1.42%)
NVO : 143.26 (+1.04%)
PRTA : 21.48 (+4.83%)
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PRTA : 21.48 (+4.83%)
AEZS : 6.65 (-3.48%)
Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial...

PRTA : 21.48 (+4.83%)
Prothena to Report First Quarter 2023 Financial Results on May 4

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 21.48 (+4.83%)
Prothena to Participate in 2023 Bank of America Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 21.48 (+4.83%)
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety...

PRTA : 21.48 (+4.83%)
WBA : 15.54 (-2.45%)
Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?

Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.

BIIB : 230.63 (+2.17%)
RHHBY : 34.0900 (+1.73%)
PRTA : 21.48 (+4.83%)
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new...

PRTA : 21.48 (+4.83%)
Prothena to Participate in Stifel 2023 Virtual CNS Days

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 21.48 (+4.83%)
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 15, 2023 – USA News Group  –  According to a 2022 study of more than 6 million patients 65 and older, the risk factor...

MRVL.VN : 0.110 (unch)
BIIB : 230.63 (+2.17%)
PRTA : 21.48 (+4.83%)
ITCI : 68.20 (-1.35%)
RHHBY : 34.0900 (+1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 23.21
2nd Resistance Point 22.67
1st Resistance Point 22.07
Last Price 21.48
1st Support Level 20.93
2nd Support Level 20.39
3rd Support Level 19.79

See More

52-Week High 77.13
Fibonacci 61.8% 55.12
Fibonacci 50% 48.32
Fibonacci 38.2% 41.53
Last Price 21.48
52-Week Low 19.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar